Biblio

Author [ Title(Desc)] Type Year
Filters: Author is Huang, Xiaojun  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
C
Fan S, Mo X, Zhang X, Xu L, Wang Y, Yan C, Chen H, Zhang Y, Cheng Y, Sun Y, et al. Clinical characteristics and outcomes of allogeneic hematopoietic stem cell transplantation recipients with coronavirus disease 2019 caused by the Omicron variant: a prospective, observational cohort study. Ann Hematol. 2024.
Tang F, Wang Y, Wang Y, Jin J, Han W, Chen Y, Yan C, Xu L, Zhang X, Huang X. The clinical outcomes of haploidentical stem cell transplantation (haplo-HSCT) for patients with therapy-related myelodysplastic syndrome: comparable to de novo myelodysplastic syndrome. Clin Exp Med. 2024;24(1):33.
Liu Y, Huang X, Fei Q, Xu L, Zhang X, Liu K, Chen Y, Chen H, Wang Y. Comparison analysis between haplo identical stem cell transplantation and matched sibling donor stem cell transplantation for high-risk acute myeloid leukemia in first complete remission. Sci China Life Sci. 2018.
Sun W, Zhang Y, Chen Y, Sun Y, Cheng Y, Wang F, Chen H, Chen Y, Yan C, Mo X, et al. Comparison of clinical features of nephrotic syndrome after haploidentical and matched donor hematopoietic stem cell transplantation. Chin Med J (Engl). 2023.
Li S-Q, Xu L, Wang Y, Zhang X-H, Chen H, Chen Y-H, Wang F-R, Han W, Sun Y-Q, Yan C-H, et al. Complement of an LSC-based MRD assay to the traditional MFC method for relapse prediction of AML: a prospective study. Blood. 2022.
Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, et al. Correction: Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol. 2023;16(1):13.
Zhu X, Jiang Q, Lu J, Sun Y, Zhao X, Yang S, Tang F, Yu W, Zhao T, Liu X, et al. COVID-19 infection in patients with haematological malignancies: A single-centre survey in the latest Omicron wave in China. Br J Haematol. 2023.
Zhao X, Lin M, Huang X. Current status and future perspective of natural killer cell therapy for cancer. Med Rev (2021). 2023;3(4):305-320.

Pages